2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

9:00AM-10:30AM: Abstract Number: 2933

Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

9:00AM-10:30AM: Abstract Number: 2911

Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status

6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

9:00AM-10:30AM: Abstract Number: 2918

Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

9:00AM-10:30AM: Abstract Number: 2930

Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

9:00AM-10:30AM: Abstract Number: 2941

Reach and Effectiveness of a Health Communications Campaign Promoting Self Management Education: Results of a Pilot Test of the Learn More. Feel Better. Campaign

6W016 ARHP Abstract: Interventions & Self-Management–ARHP III (2940–2945)

9:00AM-10:30AM: Abstract Number: 2904

Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2903

Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2924

Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort

6W011 ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Imaging of Axial SpA (2922–2927)

9:00AM-10:30AM: Abstract Number: 2901

Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2899

Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway

6W009 ACR Abstract: RA–Etiology & Pathogenesis II (2898–2903)

9:00AM-10:30AM: Abstract Number: 2906

Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2932

Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

9:00AM-10:30AM: Abstract Number: 2921

The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus

6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

9:00AM-10:30AM: Abstract Number: 2905

Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA

6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

9:00AM-10:30AM: Abstract Number: 2928

Validation of New Systemic Lupus Erythematosus Classification Criteria

6W010 ACR Abstract: SLE–Clinical V: Biomarkers, Criteria, & Outcomes (2928–2933)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].